Tracer library / [111In]BCY18469

[111In]BCY18469

Also written as [In-111]In-BCY18469

Radionuclide: In-111 t½ 4031.6 min
Modality: SPECT
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Dosimetry and biodistribution studies Preclinical only, no clinical indication yet

What it is

Compound class: EphA2-targeting bicyclic peptide (Bicycle®)
Target / mechanism: EphA2 (Erythropoietin-producing hepatocellular receptor A2) PMID 39239524
Clinical application: EphA2-overexpressing tumors (radiotheranostic application) PMID 39239524
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	—	≥98%	BCY18469	39239524 2024 Theranostics Indium-111 radiolabeling was performed by adding 65 MBq of [111In]InCl3 solution into a vial containing 144 µL of 0.1M NH4OAc(aq.) buffer

Need this precursor?We can point you to suppliers for [111In]BCY18469, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39239524. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 39239524: 'This study presents the development and comprehensive in vitro and in vivo preclinical evaluation of BCY18469, a novel EphA2-targeting bicyclic peptide-based radiotheranostic agent.'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to SPECT: the linked abstracts mention imaging 10 times vs therapy 0. Linked articles: PMID 39239524.